Tender

Regulatory Work to Secure Licence Variation for anastrozole

  • NHS England

F02: Contract notice

Notice identifier: 2021/S 000-032170

Procurement identifier (OCID): ocds-h6vhtk-02de26

Published 23 December 2021, 9:44am



The closing date and time has been changed to:

7 February 2022 - no time specified

See the change notice.

Section one: Contracting authority

one.1) Name and addresses

NHS England

Quarry House

Leeds

LS2 7UE

Contact

Liz Fleetwood

Email

liz.fleetwood1@nhs.net

Country

United Kingdom

NUTS code

UKE - Yorkshire and the Humber

Internet address(es)

Main address

https://www.england.nhs.uk//

Buyer's address

https://www.england.nhs.uk//

one.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

http://health.atamis.co.uk

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

http://health.atamis.co.uk

Tenders or requests to participate must be submitted to the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

http://health.atamis.co.uk

one.4) Type of the contracting authority

Body governed by public law

one.5) Main activity

Health


Section two: Object

two.1) Scope of the procurement

two.1.1) Title

Regulatory Work to Secure Licence Variation for anastrozole

Reference number

C52236

two.1.2) Main CPV code

  • 85149000 - Pharmacy services

two.1.3) Type of contract

Services

two.1.4) Short description

This Tender is solely for the work involved to apply for and implement a major (type II) MHRA Marketing Authorisation variation to add a new clinical indication for anastrozole. The successful Bidder will be responsible for ensuring that all relevant MHRA conditions and documentation for the Marketing Authorisation variation are met and submitted within the time limits agreed with the Authority. In return the Authority will fund actual and reasonably incurred costs associated with obtaining this licence variation only.

Full details can be found on the Atamis portal: https://health-family.force.com/s/Welcome

Closing date for submissions is 31st January 2022 at 13:00

two.1.5) Estimated total value

Value excluding VAT: £1

two.1.6) Information about lots

This contract is divided into lots: No

two.2) Description

two.2.2) Additional CPV code(s)

  • 33600000 - Pharmaceutical products

two.2.3) Place of performance

NUTS codes
  • UK - United Kingdom

two.2.4) Description of the procurement

This Tender is solely for the work involved to apply for and implement a major (type II) MHRA Marketing Authorisation variation to add a new clinical indication for anastrozole. The successful Bidder will be responsible for ensuring that all relevant MHRA conditions and documentation for the Marketing Authorisation variation are met and submitted within the time limits agreed with the Authority. In return the Authority will fund actual and reasonably incurred costs associated with obtaining this licence variation only.

two.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

two.2.6) Estimated value

Value excluding VAT: £1

two.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 April 2022

End date

31 March 2023

This contract is subject to renewal

No

two.2.10) Information about variants

Variants will be accepted: No

two.2.11) Information about options

Options: No

two.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No


Section three. Legal, economic, financial and technical information

three.1) Conditions for participation

three.1.1) Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions

Please see procurement documents

three.1.2) Economic and financial standing

Selection criteria as stated in the procurement documents

three.1.3) Technical and professional ability

Selection criteria as stated in the procurement documents


Section four. Procedure

four.1) Description

four.1.1) Type of procedure

Open procedure

four.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No

four.2) Administrative information

four.2.1) Previous publication concerning this procedure

Notice number: 2021/S 000-022199

four.2.2) Time limit for receipt of tenders or requests to participate

Originally published as:

Date

31 January 2022

Local time

1:00pm

Changed to:

Date

7 February 2022

See the change notice.

four.2.4) Languages in which tenders or requests to participate may be submitted

English

four.2.6) Minimum time frame during which the tenderer must maintain the tender

Tender must be valid until: 31 March 2023

four.2.7) Conditions for opening of tenders

Date

1 February 2022

Local time

9:00am


Section six. Complementary information

six.1) Information about recurrence

This is a recurrent procurement: No

six.4) Procedures for review

six.4.1) Review body

NHS England

Skipton House, 80 London Road

London

SE1 6LH

Country

United Kingdom

Internet address

https://www.england.nhs.uk//

six.4.2) Body responsible for mediation procedures

NHS England

Skipton House, 80 London Road

London

SE1 6LH

Country

United Kingdom

Internet address

https://www.england.nhs.uk//